



LKT Laboratories, Inc.

CPI-203

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

## Product Information

Product ID C6132  
CAS No. 1446144-04-2  
Chemical Name


Synonym

Formula C<sub>19</sub>H<sub>18</sub>ClN<sub>5</sub>OS  
Formula Wt. 399.90  
Melting Point 151.8 °C  
Purity ≥99%  
Solubility DMSO 79 mg/mL warmed  
(197.54 mM)  
Ethanol 5 mg/mL (12.5  
mM)  
Water Insoluble

Store Temp Ambient

Ship Temp Ambient

Description CPI-203 is an orally available derivative of triazolothienodiazepine JQ-1; it exhibits no sedative or anxiolytic efficacy and is currently in development as a potential anticancer compound. Like JQ-1, CPI-203 inhibits the BET bromodomain (BRD) family of proteins, including BRD4; inhibition of this protein downregulates Myc expression and IL-6 production in vitro. This compound also inhibits phosphorylation of the carboxyl-terminus domain of RNA polymerase II.



**Bulk quantities available upon request**

Product ID	Size
C6132	1 mg
C6132	5 mg
C6132	25 mg

References King B, Trimarchi T, Reavie L, et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. *Cell*. 2013 Jun 20;153(7):1552-66. PMID: 23791182.

Devaiah BN, Lewis BA, Cherman N, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. *Proc Natl Acad Sci U S A*. 2012 May 1;109(18):6927-32. PMID: 22509028.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.